Treatment of acute liver disease with diabetes!

According to RCO News AgencySemaglutide is the main part of weight loss and diabetes drugs, another use of the drug has now been discovered by an international team of researchers who can also be effective for people with liver disease.

In a clinical trial with the presence of four participants that lasted 2 weeks, the weekly dose of “Samglotide” was effective in treating the acute type of fatty liver called “non -alcoholic fatty liver” (Mash) in nearly two -thirds of patients.

Arun Sanyal, a medical professor at the University of Virginia Commonwealth, says: “The results of this study in nine countries provide strong evidence that” Samglutide “can help patients with” Mash “improve liver health, and metabolic problems.

Participants were divided into two groups. In the group that received Samglutide, 4.9 percent in their “non -alcoholic fatty liver” had a recovery process, while in the group they received was 4.9 percent.

In addition, the liver fibrosis, which occurs as a result of the liver effort to repair the damaged tissue, was reduced to 4.9 % of patients treated with Samgotide. While this amount in the placebo group was 1.5 %.

This is a great success for this drug that has shown its potential in many different areas of health.

It should be noted that the effect of placebo is relatively common and often occurs in experiments. Usually, this effect is a combination of psychological enhancement caused by the impression of treatment, plus the tendency to live a healthier and more cautious life if you are aware of the study.

“If experts are approved by experts, it can provide more treatment for patients with” Mash “and” liver fibrosis “,” says Sanial.

He added: “This is very important given the strong relationship between” Mash “and cardiovascular, metabolic and kidney disease in which” Samaglotide “in the past has shown its effectiveness benefits.

Samglutide is a hormone receptor (GLP-1) agonist, which actually acts as a natural hormone to help regulate key metabolic processes such as appetite reduction and blood sugar. This also makes it effective for the treatment of obesity and diabetes.

Regarding liver disease, it is thought that the metabolism and anti -inflammatory improvements from the drug help treat some of the main causes of “non -alcoholic fatty liver”.

This clinical trial continues and has expanded to a larger group of people for five years to investigate whether these initial recovery continues. With only one confirmed treatment for “Mash”, there is an urgent need for new options.

“Samaglotide offers a new and promising approach to millions of patients by treating liver disease and its metabolic causes,” Sanale said.

This study is published in New England Journal of Medicine.

The end of the message